



CANM 2019 ANNUAL SCIENTIFIC MEETING

RÉUNION ANNUELLE DE L'ACMN 2019

FACULTY LIST / LISTE DES CONFÉRENCIERS

Abele, Jonathan

Dr. Jonathan Abele is an Associate Professor in the Department of Radiology and Diagnostic Imaging at the University of Alberta in Edmonton. He has an active clinical practice in Nuclear Medicine, SPECT/CT, PET/CT, general Radiology and body CT Imaging and is a partner in Medical Imaging Consultants – a group of over 80 Radiologist and Nuclear Medicine physician partners. He is a member of the Residency Program Committee for Nuclear Medicine at the U of A. This program currently has 13 active Nuclear Medicine residents.

Arsenault, Frédéric

Dr Frédéric Arsenault est un nucléiste gradué de l'Université de Montréal en 2016. Il a complété sa formation par une année supplémentaire en oncologie nucléaire dans la pittoresque ville de Québec sous la supervision des Dr Buteau, Beauregard et Beaulieu. La majeure partie de son temps fut consacrée au traitement des patients atteints de tumeurs neuroendocrines par la thérapie aux radioligands, ou PRRT. Depuis le 1er juillet 2018, il est de retour à temps plein comme nucléiste au Centre Hospitalier de l'Université de Montréal.

Beaulieu, Alexis

Le Docteur Alexis Beaulieu a gradué au programme de médecine nucléaire de l'Université de Montréal en 2015, suite à quoi il s'est joint à l'équipe du CHU de Québec – Université Laval, au sein de l'équipe pré-existante de Radiothérapie personnalisée aux récepteurs peptidiques (Personalized Peptide Receptor Radiation Therapy – P-PRRT).

Il a par la suite complété une formation complémentaire – ou Fellowship – en PRRT, mais également en Radio-Ligand Therapy (RLT) au sein de l'équipe de médecine nucléaire et de Theragnostics du Prof. Rodney J. Hick en 2017-2018.

Ses intérêts et ambitions actuels incluent le développement et l'expansion des programmes de thérapie ciblées en médecine nucléaire, avec un intérêt particulier pour le cancer de la prostate.

Beauregard, Jean-Mathieu

Dr. Jean-Mathieu Beauregard, MD, MSc, FRCPC, is Assistant Professor of Nuclear Medicine at Université Laval and Clinician-Scientist at CHU de Québec - Université Laval in Quebec City, Canada. He is a Nuclear Medicine Physician cumulating over 11 years of experience in molecular imaging and PRRT of neuroendocrine tumours. Following his fellowship at the Peter MacCallum Cancer Centre (Melbourne, Australia), he started a PRRT program in Quebec City and, more recently, launched a first-of-its-kind prospective clinical trial of personalized Lu-177-octreotate PRRT. Dr. Beauregard also conducts a pre-clinical research program in which he investigates the application of novel radiosensitizing approaches for radionuclide therapy.

Bénard, François

François Bénard is the Vice President, Research at BC Cancer, a distinguished scientist at the BC Cancer Research Center and Professor in the Department of Radiology at the University of British Columbia. He holds the BC Leadership Chair in Functional Cancer Imaging. As a clinician scientist, his research interests are in positron emission tomography (PET), nuclear medicine, cancer imaging and targeted radionuclide therapy. His team developed several new radiopharmaceuticals targeting tumour receptors, notably peptides and small molecule ligands. He initiated the program that developed cyclotron production of ^{99m}Tc, for which he and his colleagues were awarded the 2015 Brockhouse Canada Prize for Interdisciplinary Research in Science and Engineering by NSERC. He has established extensive multidisciplinary collaborations, and his research activities span from radiopharmaceutical development to multicentre clinical trials.

Bennett, Paige

Paige Bennett, MD, ABNM is a Professor of Nuclear Medicine of Nuclear Medicine at Wake Forest University Health Sciences in Winston-Salem, North Carolina. In addition to her academic practice of clinical Nuclear Medicine/PET and Theranostics, she edited and authored Diagnostic Imaging: Nuclear Medicine and Specialty Imaging: PET (Amirsys/Elsevier, Inc.). Her @nuclear_radiology page on social media site Instagram is at the forefront of global nuclear medicine education in the free and open access to medical education movement (#FOAMed and #FOAMrad). She currently serves as Chair of the Women in Nuclear Medicine committee for the Society of Nuclear Medicine and Molecular Imaging. She attended University of Virginia School of Medicine, Wake Forest University Health Sciences for her Nuclear Medicine residency, and is currently obtaining a Master of Education in the Health Professions through Johns Hopkins University.

Boivin, Jonathan

Jonathan Boivin a gradué en génie physique à l'Université Laval, puis a complété une maîtrise en génie biomédical à l'Université de Montréal. Il a récemment terminé un doctorat en physique à l'Université Laval et travaille maintenant à Québec comme physicien médical clinique au service de radio-oncologie du CHU de Québec - Université Laval. Il vient également de compléter un programme de résidence en physique de la radio-oncologie dirigé par l'Université McGill. Au cours de ses études, il a mené plusieurs recherches sur le développement d'instruments de mesure de dose de rayons X au CT et en radiologie interventionnelle. Il participe désormais au déploiement d'un programme de contrôle qualité et d'optimisation des protocoles CT en imagerie médicale au sein du CHU de Québec - Université Laval.

Brown, Shannon

Shannon D. Brown, Managing Director, OncoBeta International, Munich, Germany. Previous served as OncoBeta International, Vice-President of Global Business Development.

Shannon Brown has a long track record of strong leadership with over 30 years' experience in the medical field.

Brown, 54, studied emergency medicine at the US Army Academy of Health Sciences in Ft. Sam Houston, Texas. Having had various assignments throughout the world where he managed field aid stations as well as medical clinics. After 10 years' military service, he focused his career on the pharmaceutical industry where he has held various commercial and business development positions with national and global organizations. He and his wife Karin of 26 years, have one daughter and one grandson.

Brunken, Richard

Richard C. Brunken MD is the Director of Nuclear Cardiology in the Department of Nuclear Medicine at the Cleveland Clinic, and is a Clinical Professor (Department of Radiology) in the Cleveland Clinic Lerner College of Medicine of Case Western University. He is Board Certified in Internal Medicine, Cardiology and Nuclear Medicine, and serves on the Editorial Boards of the Journal of Nuclear Medicine and the Journal of Nuclear Cardiology.

Buteau, Jean-François

Graduated from Montreal University in 2011, he underwent a radioisotope therapy fellowship with Dr. Sandy McEwan at the Cross Cancer Institute in Edmonton, Alberta from 2011 to 2012. He then joined Dr. McEwan's therapy program as a staff for one more year. He later moved back to Québec City, where he helped ramp up the NET and Diagnosis Nuclear Medical Program.

Chan, Denise

Denise Chan was born and raised in Vancouver, British Columbia where she obtained her Medical Degree from the University of British Columbia. She completed her Diagnostic Radiology and Nuclear Medicine Residency training in London, Ontario at the University of Western Ontario. She is currently a partner with EFW Radiology in Calgary, the co-lead of the Nuclear Medicine Division in the South Health Campus Hospital and a Clinical Assistant Professor at the University of Calgary. She is currently an Examiner for the Royal College of Nuclear Medicine and a Board Member at the CANM.

Dalipaj, Mary

Mary Dalipaj is a proud Nuclear Medicine Technologist who spent most of her career at the University of Ottawa Heart Institute where she was the Director of Clinical Operations in integrated cardiac imaging modalities. Her current role is as a Medical Information and Application Specialist with the Pharmaceutical Diagnostics division of GE Healthcare. She is based in Ottawa and covers North America. Published author, presenter and educator.

Dery-Jeanson, Félix

Technologue en médecine nucléaire diplômé du collège Ahuntsic en 2013. J'ai travaillé dans plusieurs centres de médecine nucléaire du Québec soit à l'Hôtel-Dieu de Sorel-Tracy, l'Hôtel-Dieu de Roberval (R.S.O. et Technologue), l'hôpital de Chicoutimi et l'Hôtel-Dieu de Québec depuis 1 an maintenant. J'ai également travaillé en recherche pour le C.I.M.S. (Centre d'imagerie moléculaire de Sherbrooke) pour le projet Ga68-Dota-Tate.

Deschamps, Xavier

Titulaire d'un baccalauréat en pharmacie de l'Université de Montréal et d'une maîtrise en pharmacie d'hôpital de l'Université Laval, Xavier Deschamps exerce la pharmacie à l'Hôtel-Dieu de Québec depuis 2005. Responsable du volet pharmacie du programme de nutrition parentérale à domicile depuis 2007, il a été quelques années chargé de cours pour la nutrition parentérale auprès des étudiants à la maîtrise en pharmacothérapie avancée de la Faculté de pharmacie de l'Université Laval. Il exerce par ailleurs principalement à la clinique pré-opératoire et à l'unité de chirurgie générale. Il est également en charge de la certification en manipulation stériles pour les produits non-dangereux des assistants-techniques en pharmacie et des pharmaciens de l'Hôtel-Dieu de Québec depuis 2012. En 2015, il s'est associé avec le service de médecine nucléaire pour la certification en manipulation stériles des technologues.

Doerr, Cynthia

Cynthia Doerr, MD, is the Director of Clinical Programs for Serene, LLC, a privately held company that develops and commercializes radiolabeled diagnostic and therapeutic products for rheumatologic, cardiovascular, and oncologic conditions in human and veterinary medicine using the isotope Sn-117m. She earned her MD at the University of Nebraska Medical Center, and completed a Fellowship in Pediatric Infectious Diseases at Baylor College of Medicine. She practiced Pediatric Infectious Diseases and Hospital Epidemiology for five years in San Antonio, Texas, and then worked in a global healthcare venture capital firm for 13 years before joining Serene in 2014.

Eddy, Katie

(Not available)

Flood, Kathy

Chief Executive Officer, American Society of Nuclear Cardiology

Ms. Flood brings more than 20 years of experience working with medical associations and health care organizations to her new role at ASNC.

Godoy, Tássia (Ribeiro Monteiro de)

Dr. Tássia Godoy MD is a Nuclear Medicine fellow at University of British Columbia affiliated Teaching Hospitals focusing on scintigraphy and PET-CT imaging, and also focusing on the expected opportunities for the development of new therapeutic agents using radioligand therapy. She completed her Nuclear Medicine training at São Paulo, Brazil, where she also completed a post-graduation in Dermatology and has worked at different private clinics and hospitals in both areas. On completion of her fellowship her aim is to go back to Brazil to work as a Nuclear Medicine specialist with emphasis in the theranostic field and in the hybrid imaging.

Guerin, Brigitte

Brigitte Guérin est titulaire de la chaire Jeanne-et-J.-Louis-Lévesque en radiobiologie à l'Université de Sherbrooke (UdeS). Professeure titulaire au Département de médecine nucléaire et de radiobiologie, elle est également chef du laboratoire de radiochimie au Centre d'imagerie moléculaire (CIMS) du CIUSSS-CHUS. Après avoir reçu son doctorat en chimie organique de l'UdeS, elle a complété une formation postdoctorale sous la direction du professeur Yvan Guindon à l'Institut de recherche clinique de Montréal, où elle a continué à travailler comme chercheur sénior jusqu'en 2002 pour ensuite occuper le poste de directrice de la chimie médicinale chez IPS Pharma Inc. En 2007, elle a accepté un poste de professeur de l'UdeS où elle a rapidement établi un programme de recherche original grâce à son savoir-faire et à son expertise en radiochimie. Depuis, elle a établi des collaborations avec de nombreux groupes, obtenant d'importants financements tout en se forgeant une excellente réputation internationale dans le domaine de la synthèse de radiotraceurs à des fins d'imagerie moléculaire. Elle a publié plus de 81 articles scientifiques dans des revues à comité de lecture, a des brevets en instance, a avancé 13 radiotraceurs du laboratoire vers la clinique, et a donné 43 conférences comme chercheur invitée dans des congrès internationaux.

Brigitte Guérin holds the Jeanne-and-J.-Louis-Lévesque Chair in Radiobiology at Université de Sherbrooke (UdeS). Full Professor at the Department of Nuclear Medicine and Radiobiology, Dr Guérin is also Head of the Radiochemistry Laboratory at CIUSSS-CHUS Molecular Imaging Centre (CIMS). After receiving her Ph.D. in organic chemistry from UdeS (1994), she completed a postdoctoral training under the supervision of Prof. Yvan Guindon at the Montréal Clinical Research Institute, staying on as Senior Research Associate until 2002 when she accepted a

position as Director of Medicinal Chemistry at IPS Pharma Inc. In 2007, she accepted a tenure-track faculty position at the UdeS Department of Nuclear Medicine and Radiobiology. She rapidly established an original radiochemistry research program as an independent researcher, based on her extensive know-how and expertise in the field of radiochemistry. She has since established very productive research collaborations with numerous research groups, securing major research funding while forging an international reputation for excellence in syntheses of radiotracers for the purposes of molecular imaging. She has published over 81 scientific articles in peer-reviewed journals, has patents pending, has advanced 13 radiotracers from the bench to clinical trial, has given 43 invited lectures at international scientific meetings, and has vulgarized her work for public media in both official languages.

Harvey, Gilles-Philippe

(Not available)

Hatazawa, Jun

(Not available)

Kairemo, Kalevi

Prof Kairemo graduated with a MSc(Eng) degree from the Department of Chemical Engineering at Helsinki University of Technology in 1980 before undertaking medical training (MD, PhD) at the University of Helsinki, Finland. He undertook specialist training in Clinical Chemistry, Nuclear Medicine, Health Care Administration and Clinical Pharmacology at Helsinki University (Central Hospital) and then had a post-doctoral research fellowship at Memorial Sloan-Kettering Cancer Center from 1989-91 and 1993 in New York.

Prof Kairemo has held posts as Professor in Clinical Chemistry at the Norwegian University of Science and Technology (1998-9), Professor in Nuclear Medicine at Uppsala University Hospital in Sweden (2001-5) and as Head of the Nuclear Medicine Division, Department of Oncology at Helsinki University Central Hospital (2004-9). Since 2009, he has been Chief of Nuclear Medicine and Molecular Radiotherapy (Theragnostics) at the Docrates Cancer Center, in Helsinki. Since 2015 he has acted as Visiting Professor in the Nuclear Medicine Department of The University of Texas MD Anderson Cancer Center.

Prof Kairemo has also held posts in industry, as Medical Director of CTT Cancer Targeting Technologies (2001-6), Medical Director of Imanext Ltd (2006-8) and Clinical Director at Advanced Accelerator Applications SA, a joint French-Italian initiative.

Prof Kairemo has wide experience in the development of tumor-seeking compounds, including monoclonal antibodies, specific phage-display peptides and cytotoxic drugs, and he has coordinated several EU Research Program proposals, including as the National Coordinator and Management Committee Member for the European Union COST Action Project (BM 0607, Targeted Radionuclide Therapy) from 2007-11. He has been developing intelligent targeting nanoparticles which contained cytotoxic compounds or tracers (also for MRI, optical or ultrasound imaging). The key targets were MMP's and leukocyte integrins. He has also been involved with e.g. radiation sensitizing, hypoxia, angiogenesis and apoptosis related targeting approaches. He has also worked with gene therapy radionuclide applications. Now develops PET-tracers for oncology, including early clinical therapy response evaluation.

Besides a few patents prof Kairemo has published more than 200 original articles in peer-reviewed journals. He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) and was President of the 7th International Conference on Radiopharmaceutical Therapy held in November 2012 in Levi in Finnish Lapland. In 2014, Dr Kairemo hosted ISORBE Symposium and Workshop "Cell Labelling

and Cell Therapies” in Helsinki. Now, he is organizing International Symposium on Radiopharmaceutical Therapy (WARMTH) in November 2018 in Helsinki.

Kamel Hasan, Olfat

(Not available)

Lafrenière, Nancy

La thérapie doit être adaptée aux besoins spécifiques de la personne pour augmenter l'efficacité et la sécurité de la démarche avec peu ou pas d'effets secondaires.

La dosimétrie est utilisée pour guider la planification du traitement. Soit le radionucléide à utiliser, la quantité de radionucléide donnée, la fréquence des traitements et l'exposition des organes cibles et des tumeurs.

La biodistribution du radionucléide est mesurée sur différents organes à risque ainsi que les tumeurs en traçant des régions d'intérêts reproductibles sur plusieurs images dans le temps.

Le rôle des technologues dans l'acquisition et la génération des images, la rigueur dans les données empiriques est primordial pour le suivi en comparant les données obtenues dans les différents cycles de traitement.

Laidley, David

Dr. David Laidley is originally from St. John’s Newfoundland where he attended Memorial University (MUN) and received both Bachelor of Science and master’s degrees. He pursued his medical training at MUN and completed his Nuclear Medicine residency training at Western University. Following residency, he completed a one-year oncology PET-CT fellowship at McGill University and a six-month Nuclear Oncology fellowship specializing in radioisotope therapy at Western.

Dr. Laidley is co-lead of the Neuroendocrine Disease Site Team at LRCP”, local PI for both the Provincial CCO Lu-177 PRRT trial and Lu-177 PSMA Vision Trial. Current member of the CCO steering committees involving both PRRT and Ga-68 DOTA-TATE.

Currently, Dr. Laidley is an Assistant Professor at Western University in the Division of Nuclear Medicine and Assistant Program Director of the Nuclear Medicine Residency Program.

Leblond, Antoine

Professeur adjoint de clinique

Faculté de médecine - Département de radiologie, radio-oncologie et médecine nucléaire

Dr. Antoine Leblond trained in nuclear medicine at the University of Montreal from 2002 to 2007. He then pursued his formation in PET/CT at the University of Washington Medical Center in Seattle (2007-2008).

Following his fellowship, he worked there for an additional two years as a physician and assistant professor. He was also Assistant Program Director for Nuclear Medicine at the University of Washington from

2008 to 2010. He came back to Montreal in July 2010 to work at the Centre Hospitalier de l'Université de Montréal (CHUM). Dr Leblond is the Program Director for Nuclear Medicine at the University of Montréal since October 2011. He is clinical assistant professor at the University of Montreal (Department of Radiology, Radio-Oncology and Nuclear Medicine). Dr Leblond is involved at many levels in his clinical and academic institutions. He has marked interest in Information Technologies.

Mawlawi, Osama

Dr. Mawlawi is a Tenured Professor of Imaging Physics and the Section Chief of Nuclear Medicine Physics at the University of Texas MD Anderson Cancer Center. He started his Medical Physics career

at Memorial Sloan Kettering Cancer Center in New York as a research assistant from 1990-1998. He later joined Columbia University School of Physicians and Surgeons as an Assistant Professor from 1998-2001 before coming to MDACC in 2001. Dr. Mawlawi has extensive expertise in PET imaging of biomarkers in preclinical applications and in Phase I-III clinical trials. His primary interest focuses on investigating factors affecting absolute quantification of PET/CT images. His ongoing research is aimed at developing novel techniques for PET/CT image acquisition, correction and reformation, as well as modeling the distribution of novel radiotracers. He has authored over 100 peer reviewed articles and book chapters and is the recipient of several grants from industry and professional societies. Dr. Mawlawi is also an active member of several professional societies such as the SNMMI, AAPM, IEEE, RSNA and ACR where he serves in various roles such as task group chair, board member, or review committee and is the past president of the American Board of Science in Nuclear Medicine (ABSNM). Dr. Mawlawi also serves on multiple institutional committees such as the IRG, CRC, RSC, and ECFS. He has won numerous awards, most recently the MD Anderson's President's Recognition for Faculty Excellence Award in 2014. Dr. Mawlawi is frequently invited as a presenter at national and international conferences. He is board certified in Nuclear Medicine Physics and instrumentation by the ABSNM and in Diagnostic Radiologic Physics by the ABR.

McEwan, Sandy

Dr. McEwan is an internationally recognized expert in the fields of radioisotope therapy, molecular imaging and imaging biomarkers. His clinical practice and clinical research interests are in thyroid cancer and neuroendocrine tumours. He has established the largest radioisotope therapy program in Canada, and with Dr Murray has developed the novel hypothesis that low-dose hypersensitivity explains the mechanism of action of this form of treatment. He introduced ¹⁷⁷Lu Octreotate to the Cross Cancer Institute in 2010.

He has been past president of the Society of Nuclear Medicine in the United States and also of the Canadian Association of Nuclear Medicine. In these roles he represented the discipline at numerous venues, including discussions with the U.S. and Canadian federal governments, the FDA, industry and other medical specialty societies. He was Special Adviser on medical isotopes to the Federal Minister of Health from 2009 to 2011, and he sits on the Nuclear Energy Agency's High-Level Group on medical isotopes. He is currently Chair of the Department of Oncology at the University of Alberta.

Minoshima, Satoshi

Satoshi Minoshima, M.D., Ph.D. is Professor and Chair in the Department of Radiology and Imaging Sciences at the University of Utah. Dr. Minoshima is a radiologist specialized in Nuclear Medicine and Molecular Imaging. His scientific contributions in the field of Neuroscience include the discovery of very early sign of Alzheimer's disease in the posterior cingulate cortex and worldwide dissemination of diagnostic statistical mapping technology. He has published over 170 peer reviewed articles and numerous book chapters, review articles, proceedings, and abstracts, and given over 300 presentations. He served as the President of the Brain Imaging Council for the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and currently serves as the SNMMI Chair of the Scientific Program Committee, SNMMI Vice President Elect, as well as the Chair of the Molecular Imaging Committee for the Radiological Society of North America (RSNA). He also works with the United Nations / International Atomic Energy Agency to advance the peaceful use of nuclear technology in medicine. Dr. Minoshima has received multiple awards including Tetalman Memorial Award in 1996 and Kuhl-Lassen Award in 2006 from the SNMMI; Gold Medal from the American Roentgen Ray Society (ARRS) in 2013; Clinical

Teaching Award of the Year in 2014; the University of Washington Presidential Entrepreneur Faculty Fellow Award in 2014; and the SNMMI Presidential Distinguished Service Award in 2016.

Ouellet, Robert

Physicien médical depuis 30 ans dans divers hôpitaux universitaires du Québec.

Pomerleau-Jobidon, Kim

J'ai complété des études en technique de médecine nucléaire au collège Ahuntsic en 1998. J'ai, par la suite, travaillé à Bathurst au Nouveau-Brunswick et au Québec comme technologue pendant quelques années. Depuis près de 10 ans, j'occupe la fonction de coordonnatrice en radioprotection au CHU de Québec – Université Laval. Mon rôle consiste à assurer la sécurité radiologique en imagerie médicale, en radio-oncologie et aux laboratoires de recherche. Je suis directement impliqué dans la gestion du programme de radioprotection et de l'enseignement de la radiation et de ses effets. Afin de parfaire mes connaissances, j'ai terminé en 2015 un baccalauréat en administration des affaires et une certification en gestion de risques.

Je suis membre de l'OTIMREPMQ en tant que technologue de médecine nucléaire et de la Canadian Risk Management association.

Pouliot, Frédéric

Dr. Pouliot is a clinical-scientist and an urologist-oncologist since 2010. He is an associate professor in the Surgery Department of the Faculty of Medicine at Université Laval. He also obtained a Ph.D. in Physiology Endocrinology at Laval University and a post-doc in molecular imaging at UCLA. He has published many articles and reviews on molecular and bioluminescence imaging. His research program has been recognized by different funding organizations such as FRQS Clinical Research Scholar-Junior 1 and 2 and Prostate Cancer Canada-Movember Clinician-Scientist and Rising Star Awards. Dr Pouliot is also involved in several national and international research clinical trials aiming to improve the prostate cancer management. His center has been the second center in Canada to image prostate cancer patients with Choline PET/CT and he hold positions on the steering committees of three prospective prostate cancer imaging trials and one radioligand therapy trial. His preclinical and clinical research interests include molecular imaging of recurrent and metastatic prostate cancers.

Probst, Stephan

Stephan Probst did a nuclear medicine residency at McGill, followed by a fellowship in PET/CT at NYU. He has been on staff at the Jewish General Hospital since 2010 and he is the Chief of Nuclear Medicine since 2013. His research focuses on PSMA PET/CT and radionuclide therapy of prostate cancer.

Rahmim, Arman

Dr. Rahmim is Associate Professor of Radiology and Physics & Astronomy, Faculties of Medicine and Science at the University of British Columbia and Senior Scientist and Provincial Medical Imaging Physicist at BC Cancer Agency. He received his MSc in Condensed Matter Physics and PhD in Medical Imaging Physics at UBC. Following his doctoral studies, he was recruited by Johns Hopkins University (JHU) to lead the High Resolution Brain PET Imaging Physics Program and pursue research at the JHU Department of Radiology. In 2018, he was recruited back to Vancouver where he conducts research in image generation and analysis, machine learning, radiomics and radionuclide therapy. He has published over 110 journal articles and 220 conference proceeding papers/abstracts, and has delivered more than 50 invited lectures

worldwide. He has participated as principal investigator or co-investigator on a range of grants towards quantitative tomographic imaging, including translation to clinical applications. Dr. Rahmim was elected as IEEE Senior Member in 2012, is President of the Physics, Instrumentation and Data Sciences (PIDS) Council of the Society of Nuclear Medicine & Molecular Imaging (SNMMI), and was awarded the John S. Laughlin Young Scientist Award by the American Association of Physicists in Medicine (AAPM) in 2016.

Rayson, Daniel

Dr. Daniel Rayson is a medical oncologist at the Queen Elizabeth II Health Sciences Centre and Professor of Medicine and Pediatrics at Dalhousie University. He completed his medical training at Dalhousie, with subsequent fellowship training in Internal Medicine and Hematology/Medical Oncology at the Mayo Clinic in Rochester, Minnesota. He is past Chair of the Nova Scotia Provincial Breast Cancer Site Team (2000-2009), current Chair of the multidisciplinary Neuroendocrine Tumor Group (2012-) and past chair of the Clinical Trial Grant Panel Review Committee of the National Cancer Institute of Canada (2006-2009). He has been the Director of the Atlantic Clinical Cancer Research Unit (ACCRU) since 2008, is on the editorial board of the Art of Oncology Section of the Journal of Clinical Oncology and has been section editor of the Cancer Narratives Section of Current Oncology since January 2013. In January 2015, he was appointed Head of the Division of Medical Oncology at the QE II Health Sciences Center.

Ross, Andrew

Royal College certified nuclear physician and radiologist period.

Has worked in Halifax for over 20 years. Currently division head of nuclear medicine at the QE2 Health Sciences Center. Professor of medicine at Dalhousie University. Current president of CANM and past chair of the Royal College Nuclear Medicine Examination Committee.

Scheiber, Christian

(Not available)

Soucy, Jean-Paul

Dr. Jean-Paul Soucy Assistant Director, BioImaging, PERFORM Centre, Concordia University and Adjunct Professor, Dpt of Neurology and Neurosurgery, McGill University; Medical Director, PET Unit, Montreal Neurological Institute. He also is a full professor (clinical) in the Department of Radiology, Faculty of Medicine, Université de Montréal.

Dr. Soucy received his Medical Degree (M.D.), and was first in his class, at the Université de Montréal's School of Medicine (1980). He conducted his residencies from 1980-1984 with the Université de Montreal and McGill University. Dr. Soucy also received a Masters Degree (M.Sc) in Neuroscience (1993) from the Université de Montréal. He received a C.S.P.Q. Nuclear Medicine (Specialty Certification of the Quebec College of Physicians) in 1984, F.R.C.P.(c) Nuclear Medicine in 1984, a D.E.S. (Specialty Diploma, Nuclear Medicine) from the Université de Montréal, as well as Board Certification, American Board of Nuclear Medicine, in 1984. He was a Post graduate Fellow of the McLaughlin Foundation at service hospitalier Frédéric Joliot, France in 1985.

Dr.Soucy has given over 200 presentations at scientific meetings world-wide, and has been invited to speak at over 70 conferences across Canada, in Brazil and the US. He is or has been a member of a variety of committees including Surveyor for the Royal College of Physicians and Surgeons of Canada since 2000, and Executive Committee Member of the Canadian Association of Nuclear Medicine. He currently is Chair of the Conjoint Committee on Accreditation of the CMA. He is a member of a number of societies including, the Society of Nuclear Medicine,

Society for Neuroscience, the Organization for Human Brain Mapping and is a founding member of the Society for Fronto-temporal Dementias.

He has published approximately over 100 abstracts in respected scientific journals, 7 book chapters, and over 50 papers in peer-reviewed journals. He has tutored and supervised medical residents and post-grad students from around the world. His research interests are in the field of cerebral blood flow quantification and image restoration with SPECT, as well as *in vivo* acetylcholine imaging in dementia and other neurodegenerative diseases using PET.

Dr Soucy has received many accolades throughout his career, in addition to those for excellence in academic performance, he is the recipient of a prestigious teaching award in two consecutive years, the Prix Esculape – Best teacher in Nuclear Medicine 1991-92, and 1992-93 from hôpital Notre-Dame.

Stevenson, Nigel

Dr. Stevenson obtained his Ph.D. at the University of London, UK in 1983 in Nuclear Physics. He then worked as a research scientist at TRIUMF, the Canadian national accelerator facility, where he went on to head up the Isotope Production group. Subsequently, he has held several commercial positions including: V.P. of Isotope Production and Research for Theragenics Corporation, COO of Trace Life Sciences and COO of Clear Vascular, Inc. Since 2015, Dr. Stevenson has served as the Chief Operating Officer of Serene, LLC – a company that is exploring the treatment of veterinary and human rheumatological conditions with radioactive products. Dr. Stevenson has organized several isotope conferences over the years including the 3rd International Conference on Isotopes held in Vancouver in September 1999 where he served as the Conference Chairperson. He has also had various roles in the International Isotope Society including that of the President of the Canadian Chapter and is presently the President of the World Council on Isotopes.

Turcotte, Eric

Éric Turcotte Dr Éric Turcotte is a specialist in nuclear medicine since 2004. He graduated from the University of Sherbrooke in 2001. He performed a two-year fellowship at the University of Washington Medical Center in Seattle with Dr. Hubert Vesselle. They worked together on several oncologic projects including the use of FLT for lung tumor imaging and artificial neural networks. In 2004, he returned to the University of Sherbrooke as an adjunct professor in the Department of Nuclear medicine and radiobiology. He is also a junior FRSQ clinician-researcher working on early chemotherapy response assessment of lymphomas with FDG and FLT PET. Promoted clinical head of the Molecular Imaging center of Sherbrooke in January 2008, the imaging center received under his administration an Establishment license to produce FDG. The imaging center also owns CTAs for FLT, NaF, FES and now works on other tracers including FET, DOPA and Gallium-68 labeled tracers. Many other clinical and fundamental projects are underway as a PI or co-PI: brain metabolism of carbon-11 AcetoAcetate in Alzheimer disease, evaluation of head and neck cancer and colon cancer with FLT, search of mARN splicing variants signature in high grade lymphomas, assessing lung nodule transthoracic biopsy quality after an FDG injection. He has been very prolific in scientific papers in oncology and PET-scan and has been an invited speaker in more than thirty meetings regarding the clinical uses of PET.

Urbain, Jean-Luc

Born in Belgium in the mid 50's, I earned my Medical Degree at the University of Louvain, Belgium, and then pursued residency training in Internal Medicine and Nuclear Medicine. I

subsequently obtained a Ph.D. in Genetics and Molecular Biology at Temple University in Philadelphia. Professor of Imaging, Medicine and Biology for more than two decades I have had the opportunity and privilege to visit hospitals and medical centers and give lecture on all continents. I consider myself as a citizen of the world.

Through my career, I have held leadership and executive positions in Medical Imaging and Medicine in Belgium at the University of Leuven, in Canada at the University of Western Ontario and in the US at Temple University, Fox Chase Cancer Center, The Cleveland Clinic, the VA Administration and now Wake Forest University. I have extensive experience and expertise in committees and boards leadership, in the management of integrated health care systems and patient advocacy groups and at regional, national and international levels of government.

As Secretary of the Belgian Society of Nuclear Medicine in the 90's I introduced a multilingual and pluralist approach to the operational tasks of the Society. As President of the Canadian Association of Nuclear Medicine (CANM 2006-2011), I have worked closely with national and international medical associations and government health authorities to mitigate major the major health and medical isotopes crises of 2007-2008, analyzed and helped establish medical resources needs, benchmarks and allocation for key medical service areas. I have also served as consultant and advisor for Pharmaceutical, Radio-pharmaceutical and Medical Systems companies. My current main interests are in Medical Isotopes Production and Supply, Patients' Education and Advocacy, Personalized Medicine and Theranostics.

As Chief of Nuclear Medicine at Wake Forest University-Baptist Medical Center, Chair of the Scientific Committee of the CANM, Chair of the SNMMI Global Initiative, President Elect of the WFNMB, I am dedicated to work tireless with all stakeholders to improve the management of patients by 1. Securing the supply of Medical Isotopes 2. Developing NM educational tools accessible to the Nuclear Medicine Communities, Patients and Referring Physicians from around the world 3. Promoting the field of Diagnostic and Therapeutic Nuclear Medicine across the globe, particularly in the underserved countries.

Wong, Rebecca

Dr. Rebecca Wong is a radiation oncologist at Princess Margaret Cancer Center, Professor of the Department of Radiation Oncology. Her clinical interests are the areas of gastrointestinal malignancies and palliative radiotherapy. She became involved in CCO's mandate to address the issue of access to radionuclide therapy for Ontario patients as the co-chair of the Cancer Care Ontario PEBC (program in evidence-based care) GI site group. She is the PI for the Ontario PRRT trial that has been open since the fall of 2016. She is a member of the CCO Radionuclide Therapy Operating Council & Executive Committee, and a member of the AJCC NET staging expert panel. She is also the Vice Chair for Education, Department of Radiation Oncology, University of Toronto.
